drugset / Trial / NCT07167966
Alzheimer's Tau Platform: Regimen A - AADvac1
Phase 2
Enrolling by invitation
450 enrolled
Paul S. Aisen
Alzheimer's Clinical Trials Consortium · collabAlzheimer's Therapeutic Research Institute · collabAxon Neuroscience SE · collabMassachusetts General Hospital · collabNational Institute on Aging (NIA) · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Timeline
- Start
- 2026-11-03
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AADvac1 | Vaccine | — | Subcutaneous |
| Subject | Donanemab | Monoclonal antibody | — | Intravenous |